Although the first-generation EGFR inhibitors, gefitinib and erlotinib, and the second-generation EGFR inhibitor afatinib have been shown to inhibit GBM cell growth, proliferation, and angiogenesis in preclinical studies, these EGFR inhibitors have not shown therapeutic efficacies in clinical trials [8, 9]. Here, EGFR is linked to glioblastoma.